2 Abstract
As COVID-19 vaccine research efforts seem to be yielding the first tangible results, the proportion of individuals needed to reap the benefits of herd immunity is a key element from a Public Health programs perspective.
This magnitude, termed the critical immunization threshold (q), can be obtained from the classical SIR model equilibrium equation, equaling (1 − 1/R0)/ ϵ, where R0 is the basic reproduction number and ϵ is the vaccine efficacy. When a significant proportion of the population is already immune, this becomes (n − 1/R0)/ ϵ, where n is the proportion of non-immune individuals. A similar equation can be obtained for short-term immunization thresholds(qt), which are dependent on Rt.
qs for most countries are between 60-75% of the population. Current qt for most countries are between 20-40%.
Therefore, the combination of gradual vaccination and other non-pharmaceutical interventions will mark the transition to the herd immunity, providing that the later turns out to be a feasible objective. Nevertheless, immunization through vaccination is a complex issue and many challenges might appear.
- COVID-19
- COVID-19 Vaccines
- basic reproduction number
- effective reproduction number
- herd immunity
- non-pharmaceutical interventions
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was obtained.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No oversight body is needed for this ecological study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos